@article{Godolphin_P-2022_93887,
title = {Association between tocilizumab, sarilumab and all-cause mortality at 28 days in hospitalised patients with COVID-19: A network meta-analysis},
author = {Godolphin, P. and Fisher, D. and Berry, L. and Derde, L. and Diaz, J. and Gordon, A. and Lorenzi, E. and Marshall, J. and Murthy, S. and Shankar-Hari, M. and Sterne, J. and Tierney, J. and Vale, C.},
month = {jul},
year = {2022},
abstract = {Background:A recent prospective meta-analysis demonstrated that interleukin-6 antagonists are associated with lower all-cause mortality in hospitalised patients with COVID-19, compared with usual care or placebo. However, emerging evidence suggests that clinicians are favouring the use of tocilizumab over sarilumab. A new randomised comparison of these agents from the REMAP-CAP trial shows similar effects on in-hospital mortality. Therefore, we initiated a network meta-analysis, to estimate pairwise associations between tocilizumab, sarilumab and usual care or placebo with 28-day mortality, in COVID-19 patients receiving concomitant corticosteroids and ventilation, based on all available direct and indirect evidence.},
volume = {17},
issue = {7},
journal = {PLoS ONE},
publisher = {Public Library of Science},
url = {https://doi.org/10.1371/journal.pone.0270668},
}
